Healthy Clinical Trial
Official title:
A Single-Center, Randomised, 4-Period, Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Effect of Food on Pharmacokinetics Following Single Doses of MIV-711 Capsule and Tablet Formulations in Healthy Volunteers
Verified date | February 2018 |
Source | Medivir |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a single-Center, Randomised, 4-Period, Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Effect of Food on Pharmacokinetics following Single Doses of MIV-711 Capsule and Tablet Formulations in Healthy Volunteers
Status | Completed |
Enrollment | 18 |
Est. completion date | February 17, 2018 |
Est. primary completion date | February 17, 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 19 Years to 55 Years |
Eligibility |
Inclusion Criteria (subset): - Healthy, adult, male or female, 19-55 years of age, inclusive, at screening. - Body mass index (BMI) = 18.5 and = 30.0 kg/m2 at screening. - Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee. - If not a menopausal female or surgically sterile male or female, subjects must be willing to practice at least one of the in the CSP described highly effective methods of birth control for at least a (partner's) menstrual cycle before and for 3 months after study drug administration. - For a female of non-childbearing potential: must have undergone one of the following sterilization procedures at least 6 months prior to the first dose: - hysteroscopic sterilization; - bilateral tubal ligation or bilateral salpingectomy; - hysterectomy; - bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 2 years prior to the first dose and follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status as per PI or designee judgment. Exclusion Criteria (subset): - History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee. - History of any illness that, in the opinion of the PI or designee, that could affect the action, absorption, or disposition of MIV-711 or may confound the results of the study or poses an additional risk to the subject by their participation in the study. - History or presence of known structural cardiac abnormalities, syncope, cardiac conduction problems (first, second, or third degree heart blocks, bundle branch block, or incomplete block, atrial fibrillation and/or paroxysmal atrial fibrillation, sick sinus syndrome or prolonged QTc interval), inappropriate sinus bradycardia, deviant ECG morphology or exercise related cardiac events. - Unable to refrain from or anticipates the use of: - Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to the first dose and throughout the study. Medication listed as part of acceptable birth control methods will be allowed. - Any drugs known to be inducers of CYP enzymes for 28 days prior to the first dose of study drug and throughout the study. Appropriate sources will be consulted by the PI or designee to confirm lack of PK/PD interaction with study drug. - Acetaminophen (up to 2 g per 24 hour period) may be permitted during the study. - Hormone replacement therapy will also be allowed. - Subjects on a stable dose (at least 3 months) of thyroid medication will be allowed. - An inability to follow a standardized diet and meal schedule or inability to fast, as required during the study. |
Country | Name | City | State |
---|---|---|---|
United States | Celerion | Lincoln | Nebraska |
Lead Sponsor | Collaborator |
---|---|
Medivir |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Area under the concentration-time curve, from time 0 to the last observed non-zero concentration (t) (AUC0-t) | The PK of MIV-711 following administration of single oral doses of capsule and tablet formulations under fasting and fed conditions in healthy subjects. The evaluation will be made between the formulations. | 0 to 72 hours post dose | |
Primary | Area under the concentration-time curve, from time 0 extrapolated to infinity (AUC0-inf) | The PK of MIV-711 following administration of single oral doses of capsule and tablet formulations under fasting and fed conditions in healthy subjects. The evaluation will be made between the formulations. | 0 to 72 hours post dose | |
Primary | Maximum observed concentration (Cmax) | The PK of MIV-711 following administration of single oral doses of capsule and tablet formulations under fasting and fed conditions in healthy subjects. The evaluation will be made between the formulations. | 0 to 72 hours post dose | |
Primary | Time to reach maximum observed concentration (Tmax) | The PK of MIV-711 following administration of single oral doses of capsule and tablet formulations under fasting and fed conditions in healthy subjects. The evaluation will be made between the formulations. | 0 to 72 hours post dose | |
Primary | Apparent terminal elimination rate constant (Kel) | The PK of MIV-711 following administration of single oral doses of capsule and tablet formulations under fasting and fed conditions in healthy subjects. The evaluation will be made between the formulations. | 0 to 72 hours post dose | |
Primary | Apparent terminal elimination half-life (T½) | The PK of MIV-711 following administration of single oral doses of capsule and tablet formulations under fasting and fed conditions in healthy subjects. The evaluation will be made between the formulations. | 0 to 72 hours post dose | |
Secondary | The number and severity of AEs/SAE | Safety and tolerability of MIV-711 measured by number and severity of AEs/SAEs | from study start until 7+/-2 days after the last study drug administration | |
Secondary | The number of clinically significant abnormal lab results | Safety and tolerability of MIV-711 measured by number of clinical significant abnormal lab results. | from study start until 7+/-2 days after the last study drug administration | |
Secondary | The number of clinically significant ECG abnormalities | Safety and tolerability of MIV-711 measured by number of clinical significant ECG abnormalities. | from study start until 7+/-2 days after the last study drug administration | |
Secondary | The number of clinically significant physical examination abnormalities | Safety and tolerability of MIV-711 measured by number of clinical significant physical examination abnormalities. | from study start until 7+/-2 days after the last study drug administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |